Cancer-specific chemotherapeutic strategy based on the vitamin K3 mediated ROS regenerative feedback and visualized drug release in vivo. (December 2018)

• Record Type: Journal Article
• Authors: Yang, Gang-Gang; Zhang, Hang; Zhang, Dong-Yang; Cao, Qian; Yang, Jing; Ji, Liang-Nian; Mao, Zong-Wan
• Is Part Of: Biomaterials. Volume 185(2018)
• Page Start: 73
• Page End: 85
• Publication Date: 2018-12
• Subjects: Cancer-specific chemotherapy -- ROS regenerative feedback -- Visualized drug release -- Vitamin K3 -- Ruthenium complex; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2018.08.065
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: A promising theranostic nanosystem VK3-CPT@Ru-CD is designed and fabricated by the host-guest driven self-assembly between the fluorescent adamantine-functionalized Ru(II) complexes and the ROS-labile-cyclodextrin modified thioketal linkers, in which anticancer drug camptothecin (CPT) and vitamin K3 (VK3) are effectively co-encapsulated. On account of the generative feedback between the intracellular redox cycling of VK3 and the high degree of ROS-triggered collapse of nanoparticles, VK3-CPT@Ru-CD can facilitate cancer-specific ROS amplification and drug release selectively in cancer cells, thus realizing the selective killing of tumor with minimal side-effects both in vitro and in vivo, the therapeutic effect of which is more prominent than the free anti-cancer drugs. More interestingly, the menadione structure of encapsulated VK3 can effectively quench the inherent fluorescence of Ru-CD, and a fluorescence lightening up phenomenon is observed accompanied with the ROS-triggered drug release, which can be utilized for real-time tracking of drug release in vitro and in vivo. Graphical abstract: A promising self-assembled theranostic nanosystemVK3-CPT@Ru-CD is prepared for the selective killing of tumor and the real-time tracking of drug release in vitro and in vivo based on the vitamin K3 mediated cancer-specific ROS amplification.